drugset / Trial / NCT04031703
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, multisite, randomized, open-lable Phase III clinical trial (PATTERN study) comparing Paclitaxel Plus Carboplatin versus Anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer
Timeline
- Start
- 2011-01-01
- Primary completion
- 2016-04-20
- Completion
- 2016-04-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Comparator | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Comparator | Docetaxel | Small molecule | 100 mg/m2 | Intravenous |
| Comparator | Epirubicin | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Comparator | fluorouracil | Small molecule | 500 mg/m2 | — |